Skip to main content
EnglishEN
European Commission logo print header

Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions

Project description

DEENESFRITPL

Identifying reasons for patients’ negative response to treatment

The identification of the molecular mechanisms that can positively or negatively influence a patient’s response to medical treatment is a key issue among health practitioners. A study promoted by 3TR, a consortium of university institutions, SMEs and leading pharmaceutical companies, will address this issue. This EU-funded project will apply bioinformatics and control methods to collect and analyse data from blood, tissues and other fluids during the entire treatment process. It will create a centralised data platform for better management and implement an inclusive molecular and clinical picture of patients experiencing similar diseases. The project intends to explain the role that our microbiome, genetics and regulatory genomics play during treatment.

Objective

3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The molecular identification of groups of patients to whom a drug will benefit, will allow focusing on those who are drug orphan. Harmonization of data from existing academy or industry-sponsored studies will identify biomarkers to inform a new collection. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a de novo observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Because the studies will be at different phases of progression, a carrousel model of work was designed for input and output of data to be continuously analysed, and interpreted, to inform those measurements to be undertaken and allow cross-validation of results. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression. The working aims of 3TR are: 1) establish a centralized data management platform; 2) perform comprehensive molecular and clinical characterisation of a prospective patient cohort; 3) establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods; 4) identify sets of predictive biomarkers of response/non-response to therapies; 5) improve the competitiveness of European industry and support development of novel solutions. 3TR will sustain beyond the project end the samples and its knowledge base. 3TR will challenge and revolutionize the conventional single-disease based approach with important implications in future disease treatment.

Fields of science

Keywords

Programme(s)

Topic(s)

Call for proposal

H2020-JTI-IMI2-2018-14-two-stage

See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.
Net EU contribution
€ 9 806 529,68
Address
Avenida americo vespucio 15 edif s2
41092 Sevilla
Spain

See on map
Region
Sur Andalucía Sevilla
Activity type
Research Organisations
Links
Other funding
€ 0,00

Participants (83)

Share this page

Download

EC signature date 22 August 2019
Last update: 30 June 2023

My Booklet

Permalink: https://cordis.europa.eu/project/id/831434

European Union, 2023